• Entrada Therapeutics highlighted 2026 as a key catalyst year, led by multiple readouts across Duchenne muscular dystrophy exon-skipping programs ENTR-601-44 and ENTR-601-45.
• Phase 1/2 ELEVATE-44-201 Cohort 1 for ENTR-601-44 showed a favorable safety profile at 6 mg/kg, with no serious treatment-emergent adverse events or discontinuations.
• Cohort 1 showed a statistically significant post hoc improvement in Time to Rise velocity versus placebo, with mean change from baseline of 0.08 rises/second; mean change versus placebo of 0.115.
• ENTR-601-45 Cohort 1 data is expected mid-2026; ENTR-601-44 Cohort 1 open-label data and Cohort 2 multiple-ascending-dose data are expected by year-end 2026.
• Presentation outlined a potential USD 5 billion annual U.S. DMD market opportunity across exons 44, 45, 50, 51, cited cash runway into Q3 2027, cited Vertex-partnered VX-670 in DM1 with milestone potential up to USD 485 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Entrada Therapeutics Inc. published the original content used to generate this news brief on May 07, 2026, and is solely responsible for the information contained therein.